SCHEMBL10160985

SCHEMBL10160985

Cc1ccc(C(=O)Nc2ccc3c(c2)NC(=O)C3(C)C)c(N[C@@H]2CCNC2)c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.43
MAPK14 Q16539 2/20 0.40
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
RAB9A P51151 1/20 0.36
BRD4 O60885 2/20 0.36
ATAD2 Q6PL18 2/20 0.36
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
SYK P43405 2/20 0.35
KCNH2 Q12809 2/20 0.35
MAPK3 P27361 1/20 0.35
MAPK1 P28482 1/20 0.35
AURKB Q96GD4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10160982 1.00 FLT3 (0.43) FLT3MAPK14KDM4EALDH1A1RAB9A
SCHEMBL10160202 0.94 MAPK14 (0.41) FLT3MAPK14KDM4EALDH1A1RAB9A
SCHEMBL10129645 0.88 FLT3 (0.47) FLT3
SCHEMBL10129642 0.88 FLT3 (0.47) FLT3
SCHEMBL10129624 0.82 TRPV4 (0.40) FLT3BRD4MAPK1
SCHEMBL10160970 0.76 TRPV1 (0.45) FLT3SYK
SCHEMBL10160007 0.76 TRPV1 (0.45) FLT3SYK
SCHEMBL10477973 0.73 MEN1 (0.56) MAPK14KDM4EALDH1A1RAB9AMAPT
SCHEMBL10160329 0.70 TRPV1 (0.46) SYK
SCHEMBL9313195 0.70 MAPK14 (0.47) MAPK14ATAD2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 FLT3 4496/4885MAPK14 2764/4885KDM4E 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.